Navigation Links
Takeda Announces PDUFA Action Date for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
Date:11/1/2011

DEERFIELD, Ill., Nov. 1, 2011 /PRNewswire/ -- Takeda Global Research & Development Center, Inc., (Takeda) announced that the U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) action date of January 25, 2012 for the review of its investigational type 2 diabetes therapy alogliptin, and the fixed-dose combination therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone in a single tablet.  

Currently, the FDA is reviewing the new drug applications (NDA) for the investigational therapies, which were resubmitted on July 25, 2011; the FDA has categorized these as Class 2 responses, requiring up to six months for review. Alogliptin is a selective dipeptidyl peptidase IV inhibitor (DPP-4i) under investigation in the United States (U.S.) for the treatment of type 2 diabetes as an adjunct to diet and exercise. Discovered by Takeda San Diego, Inc., alogliptin is designed to slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide), which play a role in regulating blood glucose levels. Pioglitazone was approved in 1999 for the treatment of type 2 diabetes as an adjunct to diet and exercise. If approved, alogliptin/pioglitazone will be the first type 2 diabetes treatment option in the U.S. to include both a DPP-4 inhibitor and a thiazolidinedione (TZD) in a single tablet.

According to the International Diabetes Federation, a staggering 285 million individuals were living with diabetes worldwide in 2010.

"As recent figures indicate that diabetes continues to be a serious global health challenge, Takeda remains deeply committed to researching new and important therapeutic options for patients living with type 2 diabetes," said David Recker, M.D., senior vice president, clinical science, Takeda Global Research & Development Center. "Phase 3 studies have demonstrated that the combination of a
'/>"/>

SOURCE Takeda Global Research & Development Center, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
2. Takeda Completes Acquisition and Names New CEO of Nycomed
3. Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program
4. Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
5. Takeda Responds to U.S. Food and Drug Administration Update to Safety Review of ACTOS (pioglitazone HCl)
6. Takeda to Acquire Nycomed
7. Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
8. Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
9. Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takedas DEXILANT®
10. Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
11. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013  Viral hepatitis is an ... 75 percent of those with hepatitis C are unaware they ... Testing and Awareness Day in the U.S. House of Representatives ... the Rayburn Foyer of the Rayburn House Office Building in ... American Association for the Study of Liver Diseases ( AASLD ...
(Date:5/22/2013)... MUNICH , May 22, 2013 JenaValve ... transcatheter aortic valve implantation (TAVI) systems for the treatment of ... the J enaValve Eval U ation of Long Term ... ients with S E vere Ao R tic Stenosis (JUPITER) ... is a post-market registry to evaluate five-year long term safety ...
(Date:5/22/2013)... the 3% of the population that suffer from hyperhidrosis, ... and disabling.  While more than half of these people ... is a serious medical condition.  Finally, there is a ... Dr. Bruce Katz , Director ... New York , is leading an approved ...
Breaking Medicine Technology:Hepatitis Awareness: Bringing Attention to a Silent Epidemic 2First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 2First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 3First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 4Is There Finally A Way To Stop Severe Excessive Sweating? 2
... , , MELVILLE, N.Y., Nov. 30 ... health care products and services, announced today that Steven Paladino, the ... the NASDAQ OMX 23rd Investor Program on Tuesday, December 1, 2009. ... London. , Henry Schein,s presentation is scheduled to begin at ...
... , NEW YORK, Nov. 30 ... report is available in its catalogue: , ... to 2015 , http://www.reportlinker.com/p0166515/Europe-Ophthalmic-Devices-Investment-Opportunities-Analysis-and-Forecasts-to-2015.html , ... to 2015 , Summary , This ...
Cached Medicine Technology:Henry Schein to Present at the NASDAQ OMX 23rd Investor Program 2Reportlinker Adds Europe Ophthalmic Devices Investment Opportunities, Analysis and Forecasts to 2015 2Reportlinker Adds Europe Ophthalmic Devices Investment Opportunities, Analysis and Forecasts to 2015 3Reportlinker Adds Europe Ophthalmic Devices Investment Opportunities, Analysis and Forecasts to 2015 4Reportlinker Adds Europe Ophthalmic Devices Investment Opportunities, Analysis and Forecasts to 2015 5Reportlinker Adds Europe Ophthalmic Devices Investment Opportunities, Analysis and Forecasts to 2015 6Reportlinker Adds Europe Ophthalmic Devices Investment Opportunities, Analysis and Forecasts to 2015 7Reportlinker Adds Europe Ophthalmic Devices Investment Opportunities, Analysis and Forecasts to 2015 8Reportlinker Adds Europe Ophthalmic Devices Investment Opportunities, Analysis and Forecasts to 2015 9Reportlinker Adds Europe Ophthalmic Devices Investment Opportunities, Analysis and Forecasts to 2015 10Reportlinker Adds Europe Ophthalmic Devices Investment Opportunities, Analysis and Forecasts to 2015 11Reportlinker Adds Europe Ophthalmic Devices Investment Opportunities, Analysis and Forecasts to 2015 12Reportlinker Adds Europe Ophthalmic Devices Investment Opportunities, Analysis and Forecasts to 2015 13Reportlinker Adds Europe Ophthalmic Devices Investment Opportunities, Analysis and Forecasts to 2015 14Reportlinker Adds Europe Ophthalmic Devices Investment Opportunities, Analysis and Forecasts to 2015 15Reportlinker Adds Europe Ophthalmic Devices Investment Opportunities, Analysis and Forecasts to 2015 16
(Date:5/22/2013)... Thompson HealthDay Reporter , , WEDNESDAY, May 22 ... back pain are more likely to attempt suicide, whether ... psychiatric condition, according to a new study. "Clinicians ... be aware they are at increased risk of suicide," ... Serious Mental Illness Treatment Resource and Evaluation Center in ...
(Date:5/22/2013)... Successful Therapy for Parents program, ... in the Silver Lake community of Los Angeles ... progression to existing Parents and Couples counseling programs. ... therapy has always been suggested, but now it's ... specializes in all aspects of relationships ...
(Date:5/22/2013)... Bodybuilding.com is giving back to those who have ... be donating $1 from EVERY purchase made between 12:01am – ... grateful for the men and women who have served our ... founder of Bodybuilding.com. “It’s an honor to give back to ... USA is an amazing organization that supports our nation’s veterans ...
(Date:5/22/2013)... According to a May 14, 2013 US ... for Breast Cancer Surgery,” modern medical technology has given women ... disease in a whole new light. Since the new approach ... breast cancer and mastectomies with greater hope for ... introduction of plastic surgery to oncology, women had little choice ...
(Date:5/22/2013)... 22, 2013 Today, Zane Benefits, Inc. ... Insurance Exchange . Zane Benefits, which provides comprehensive and ... the leader in defined contribution plans and ... Benefits’ website, beginning in 2014 as part of the ... and small businesses will become available through new state ...
Breaking Medicine News(10 mins):Health News:Migraine, Chronic Back Pain Tied to Higher Suicide Risk 2Health News:Migraine, Chronic Back Pain Tied to Higher Suicide Risk 3Health News:Patricia O’Laughlin Psychotherapy of Los Angeles Now Seeing Adults, Teens and Young Children 2Health News:In the Spirit of Memorial Day, Bodybuilding.com is Donating a Portion of Their Sales to Hire Heroes 2Health News:Breast Augmentation – New Option for Breast Cancer Surgeries 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 3
... MONDAY, Dec. 5 (HealthDay News) -- There,s been a large increase ... States since 2002, a trend that may help ease concerns about ... analyzed national data and found that the number of RNs aged ... fell to fewer than 110,000 by 1991 and remained low for ...
... University of Kentucky researchers recently received a $225,000 grant ... The grant gives the team $225,000 for the ... that could total $675,000. It is funded by the ... Rural Cancer Prevention Center. Published studies have shown ...
... By Serena Gordon HealthDay Reporter , MONDAY, Dec. ... with asthma is currently using a preventive medication, according to ... percent of kids during the late 1980s. Preventive ... up, and guidelines from the U.S. National Asthma Education and ...
... -- Teenagers with autism who also have epilepsy often ... The combination means that certain behaviors common among autistic ... of their faces -- could increase their risk for ... 14 percent of children with epilepsy, the rate jumps ...
... and non-obese children found that low vitamin D levels are ... risk factors for type 2 diabetes. This study was accepted ... Endocrinology & Metabolism (JCEM). High rates of vitamin ... studies have linked low vitamin D levels to cardiovascular disease ...
... , SATURDAY, Dec. 3 (HealthDay News) -- Seizures ... during menstruation or ovulation, researchers have found. ... at the University of California, Irvine, examined the trend ... among a group of women aged 19 to 50. ...
Cached Medicine News:Health News:Good News for Those Worried About U.S. Nursing Shortage 2Health News:University of Kentucky researchers awarded CDC grant to study cancer survival in Appalachia 2Health News:More Children Using Preventive Asthma Drugs: Study 2Health News:More Children Using Preventive Asthma Drugs: Study 3Health News:Low vitamin D levels may contribute to development of Type 2 diabetes 2Health News:Epileptic Seizures May Worsen During Menstrual Cycle 2
... Revision Knee System features ... femoral replacement options. The centerpiece ... Rotating Hinge Knee, promotes the ... and is designed for distribution ...
The Advance stemmed medial-pivot knee is a revision knee that provides unique and competitive features....
... LCCK Femoral Component is intended for ... due to inadequate mediolateral, anteroposterior and ... and/or stem extensions due to inadequate ... available with a non-coated fixation surface. ...
The Duracon system provides superb articular conformity throughout the range of motion, reducing contact stresses generally associated with wear....
Medicine Products: